CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 326 enrolled
Drug / intervention
Albendazole +2 moredrug
Likely dose
Albendazole 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02725255
NCT02725255Phase 3Completed

Design and Clinical Evaluation of a School Meal With Deworming Properties

Kenya Medical Research Institute·interventional·Posted Mar 31, 2016·Updated Sep 7, 2016

In Brief

A Phase 3 clinical trial evaluating Ujiplus, Albendazole, and 1 other intervention for Helminthiasis and 2 related conditions. Completed, enrolled 326 participants.

Detailed Summary

Intestinal parasites (IP) are among the world's neglected tropical diseases. Morbidity due to IPs is greatest in school-age children who typically have the highest burden of infection. In 2001, WHO passed a resolution for the use of large-scale mass drug administration (MDA) of antihelminthic drugs to deworm children in developing countries. Though initially effective, there is concern that MDA might not be sustainable over extended periods especially considering the large children populations and the high frequency of dosing. Further, the MDAs exert increasing drug pressure on parasite populations, a circumstance that is likely to favor parasite genotypes that can resist anthelmintic drugs. There is hence a need for alternatives that are not only affordable and sustainable but easier to implement in the long term with a minimal chance of development of resistance. The investigators propose to develop and test the feasibility of a corn porridge meal fortified with papaya fruit extracts that have been shown to have antihelminthic properties. The investigators intend to evaluate its efficacy when given through school feeding programs and compare the outcome with albendazole- the recommended MDA agent for deworming school children. The investigators will design and formulate the product and test it among children in three primary schools in Western Kenya.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 31, 2016
Enrollment StartMay 1, 2015
Primary CompletionNov 1, 2015
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.3 years ago

Interventions

Ujiplusdietary

Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.

Albendazoledrug

400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.

ujidietary

maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.